Abstract

There are significant gaps in gonococcal susceptibility data particularly in high-burden countries. Laboratory detection of gonococci with reduced susceptibility to azithromycin and cephalosporins is of particular concern. Coordinated and standardised laboratory testing approaches that ensure quality assurance are vital to detect emerging resistance and optimise treatment.

This presentation will explore current gaps and identify opportunities, including roles of laboratory networks, in building regional diagnostic capacity.